Inflammatory gene expression in whole blood cells after EPA vs. DHA supplementation: Results from the ComparED study

Atherosclerosis. 2017 Feb:257:116-122. doi: 10.1016/j.atherosclerosis.2017.01.025. Epub 2017 Jan 20.

Abstract

Background and aims: Whether EPA and DHA exert similar anti-inflammatory effects through modulation of gene expression in immune cells remains unclear. The aim of the study was to compare the impact of EPA and DHA supplementation on inflammatory gene expression in subjects at risk for cardiometabolic diseases.

Methods: In this randomized double-blind crossover trial, 154 men and women with abdominal obesity and low-grade inflammation were subjected to three 10-wk supplementation phases: 1) EPA (2.7 g/d); 2) DHA (2.7 g/d); 3) corn oil (3 g/d), separated by a 9-wk washout. Pro- and anti-inflammatory gene expression was assessed in whole blood cells by RT-qPCR after each treatment in a representative sample of 44 participants.

Results: No significant difference was observed between EPA and DHA in the expression of any of the genes investigated. Compared with control, EPA enhanced TRAF3 and PPARA expression and lowered CD14 expression (p < 0.01) whereas DHA increased expression of PPARA and TNFA and decreased CD14 expression (p < 0.05). Variations in gene expression after EPA and after DHA were strongly correlated for PPARA (r = 0.73, p < 0.0001) and TRAF3 (r = 0.66, p < 0.0001) and less for TNFA (r = 0.46, p < 0.005) and CD14 (r = 0.16, p = 0.30).

Conclusions: High-dose supplementation with either EPA or DHA has similar effects on the expression of many inflammation-related genes in immune cells of men and women at risk for cardiometabolic diseases. The effects of EPA and of DHA on anti-inflammatory gene expression may be more consistent than their effects on expression of pro-inflammatory genes in whole blood cells.

Trial registration: ClinicalTrials.gov NCT01810003.

Keywords: Docosahexaenoic acid; Eicosapentaenoic acid; Immune cells; Inflammation; Omega-3; Peroxisome proliferator-activated receptor alpha; TNF receptor associated factor 3.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anti-Inflammatory Agents / administration & dosage*
  • Blood Cells / drug effects*
  • Blood Cells / immunology
  • Blood Cells / metabolism
  • C-Reactive Protein / genetics
  • C-Reactive Protein / metabolism
  • Cross-Over Studies
  • Dietary Supplements
  • Docosahexaenoic Acids / administration & dosage*
  • Double-Blind Method
  • Eicosapentaenoic Acid / administration & dosage*
  • Female
  • Gene Expression Regulation
  • Humans
  • Inflammation / blood
  • Inflammation / diagnosis
  • Inflammation / drug therapy*
  • Inflammation / genetics
  • Inflammation Mediators / blood*
  • Male
  • Middle Aged
  • Obesity, Abdominal / blood
  • Obesity, Abdominal / diagnosis
  • Obesity, Abdominal / drug therapy*
  • Obesity, Abdominal / genetics
  • Quebec
  • Time Factors
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Inflammation Mediators
  • Docosahexaenoic Acids
  • C-Reactive Protein
  • Eicosapentaenoic Acid

Associated data

  • ClinicalTrials.gov/NCT01810003

Grants and funding